

15 April 2021

Direct Healthcare Professional Communication

EYLEA 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe

Dear Healthcare professional,

Bayer plc, in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA), would like to inform you of the following.

Summary

- **Cases of increased intraocular pressure have been reported more frequently (estimated up approximately seven-fold) when using the Eylea pre-filled syringe, compared with administration with Luer-lock syringe of Eylea solution for injection in a vial.**
- **Incorrect handling in the preparation and injection is suspected as the most probable root cause of the observed cases of increased intraocular pressure with the Eylea pre-filled syringe. Injections should be performed by health care professionals familiar with the handling of this presentation.**
- **Correct handling of the pre-filled syringe and training are key to mitigate this risk:**
 - **use a 30G x 1/2 inch (13 mm) injection needle;**
 - **always check that the excess volume/air bubbles in the pre-filled syringe is eliminated before use: the base of the plunger dome (not the tip of the dome) must be aligned with the black dosing line on the syringe (see below);**
 - **carefully depress the plunger rod;**
 - **administer the exact recommended dose and do not inject any residual volume, as increased injection volume can lead to clinically relevant intraocular pressure elevation.**
- **Evaluate the patient's vision and monitor intraocular pressure immediately after the intravitreal injection.**

Background information

Eylea pre-filled syringe is indicated in adults for the treatment of:


- neovascular (wet) age-related macular degeneration (AMD)
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
- visual impairment due to diabetic macular oedema (DME)
- visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Intraocular pressure increase is a known adverse drug reaction associated with intravitreal injections in general, including the use of Eylea. A seven-fold higher reporting rate of increased intraocular pressure has been reported with the pre-filled syringe (approximately 1.1 cases per 10,000 sold pre-filled syringes versus 0.15 cases per 10,000 sold vials) following the recent European launch of this product in April 2020. There have been reports of transient increases of the intraocular pressure and

reversible visual impairment after intravitreal injections. Of the cases with known outcome, the majority resolved without permanent sequelae.

No quality defects have been detected with Eylea pre-filled syringes or the solution being injected. After further review of the reported cases, an administration of excessive product due to incorrect handling in the preparation and injection is suspected as the cause of the increased intraocular pressure. Further, Eylea pre-filled syringe is a glass syringe with a rubber plunger that requires slightly more force to be used compared to plastic syringes (such as the ones used with the vial presentation). In order to further minimise this risk, the following recommendations on appropriate handling of the Eylea pre-filled syringe should be strictly followed:

- A 30 gauge x ½ inch (13 mm) injection needle should be used.
- To eliminate all bubbles and to expel excess medicinal product, the plunger must be correctly positioned. **The base of the plunger dome** (not the tip of the dome) must be aligned with the black dosing line on the syringe, as described in section "Instructions for use of pre-filled syringe" of the product information and in the figure below.
- When administering the dose into the eye, the plunger rod must be carefully depressed with constant pressure until the plunger reaches the bottom of the syringe. A small residual volume of solution may be observed in the syringe after the plunger has reached the bottom of the syringe. Do not attempt to administer it by exerting additional pressure on the plunger.



Intraocular pressure should be monitored, and appropriate treatment should be instituted, if necessary. Immediately after the intravitreal injection:

- Evaluate vision (hand movement or finger counting).
- Appropriate monitoring of intraocular pressure may consist of a check for perfusion of the optic nerve head or tonometry. Sterile equipment for paracentesis should be available.

It is recommended to consult the training materials provided and the distributed information on the correct use of the pre-filled syringe presented in the prescriber guide and injection video of the educational materials for Eylea. The educational materials including the patient guide are also available on the eMC website www.medicines.org.uk or can additionally be made available on request, along with training sessions.

The product information and the educational material for healthcare professionals are being updated to contain additional instructions/recommendations about the handling of the pre-filled syringe to mitigate the risk of intraocular pressure increase.

Call for reporting

Healthcare professionals should report suspected adverse events suspected to be associated with the use of Eylea to the MHRA through the Yellow Card Scheme. Report via

- the Yellow Card website <https://yellowcard.mhra.gov.uk/>
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS, SystemOne, Vision, MiDatabank) for healthcare professionals.


Suspected side effect can also be reported by calling 0800 731 6789 for free.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Company contact information

For further questions or additional information on the correct use of the Eylea pre-filled syringe, please contact the medical information department at Bayer plc at the following e-mail address: medical.information@bayer.co.uk or phone number: 0118 206 3116

Yours faithfully,



Dr Melissa Rowe
Director of Medical Affairs, Specialty Medicine
Bayer plc